Harvard Bioscience, Inc. (HBIO) Stake Increased by EAM Investors LLC
EAM Investors LLC lifted its holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 137.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 266,078 shares of the medical instruments supplier’s stock after purchasing an additional 154,004 shares during the quarter. EAM Investors LLC’s holdings in Harvard Bioscience were worth $1,397,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of the company. Strs Ohio boosted its position in shares of Harvard Bioscience by 21.8% in the 3rd quarter. Strs Ohio now owns 96,681 shares of the medical instruments supplier’s stock worth $507,000 after purchasing an additional 17,281 shares in the last quarter. Essex Investment Management Co. LLC boosted its position in shares of Harvard Bioscience by 4.3% in the 3rd quarter. Essex Investment Management Co. LLC now owns 521,874 shares of the medical instruments supplier’s stock worth $2,740,000 after purchasing an additional 21,330 shares in the last quarter. Engineers Gate Manager LP acquired a new stake in shares of Harvard Bioscience in the 3rd quarter worth $112,000. Mackay Shields LLC acquired a new stake in shares of Harvard Bioscience in the 2nd quarter worth $160,000. Finally, Rhumbline Advisers acquired a new stake in shares of Harvard Bioscience in the 2nd quarter worth $164,000. 73.59% of the stock is owned by hedge funds and other institutional investors.
HBIO has been the subject of a number of recent analyst reports. ValuEngine cut Harvard Bioscience from a “buy” rating to a “hold” rating in a research report on Tuesday, November 13th. Zacks Investment Research raised Harvard Bioscience from a “hold” rating to a “buy” rating and set a $6.50 price objective for the company in a research report on Wednesday, August 1st.
Harvard Bioscience (NASDAQ:HBIO) last issued its earnings results on Thursday, October 25th. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.04. The company had revenue of $28.71 million during the quarter, compared to analyst estimates of $28.50 million. Harvard Bioscience had a positive return on equity of 5.54% and a negative net margin of 4.18%. Analysts forecast that Harvard Bioscience, Inc. will post 0.12 EPS for the current fiscal year.
In related news, CFO Robert E. Gagnon sold 8,889 shares of the firm’s stock in a transaction on Wednesday, August 29th. The stock was sold at an average price of $5.77, for a total value of $51,289.53. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2018/11/22/harvard-bioscience-inc-hbio-stake-increased-by-eam-investors-llc.html.
About Harvard Bioscience
Harvard Bioscience, Inc develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names.
Read More: What are the benefits of a balanced fund?
Want to see what other hedge funds are holding HBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harvard Bioscience, Inc. (NASDAQ:HBIO).
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.